Lipoic Acid Improves Nerve Blood Flow, Reduces Oxidative Stress, and Improves Distal Nerve Conduction in Experimental Diabetic Neuropathy

DOI PDF 被引用文献5件
  • Masaaki Nagamatsu
    Neurophysiology Laboratory, Department of Neurology Mayo Foundation, Rochester, Minnesota
  • Kim K Nickander
    Neurophysiology Laboratory, Department of Neurology Mayo Foundation, Rochester, Minnesota
  • James D Schmelzer
    Neurophysiology Laboratory, Department of Neurology Mayo Foundation, Rochester, Minnesota
  • Angel Raya
    Experimental Toxicology and Neurotoxicology Unit, Department of Physiology, School of Medicine and Dentistry, University of Valencia Valencia, Spain
  • Debra A Wittrock
    Neurophysiology Laboratory, Department of Neurology Mayo Foundation, Rochester, Minnesota
  • Hans Tritschler
    ASTA Medica Frankfurt, Germany
  • Phillip A Low
    Neurophysiology Laboratory, Department of Neurology Mayo Foundation, Rochester, Minnesota

抄録

<jats:sec> <jats:title>OBJECTIVE</jats:title> <jats:p>To determine whether lipoic acid (LA) will reduce oxidative stress in diabetic peripheral nerves and improve neuropathy.</jats:p> </jats:sec> <jats:sec> <jats:title>RESEARCH DESIGN AND METHODS</jats:title> <jats:p>We used the model of streptozotocin-induced diabetic neuropathy (SDN) and evaluated the efficacy of LA supplementation in improving nerve blood flow (NBF), electrophysiology, and indexes of oxidative stress in peripheral nerves affected by SDN, at 1 month after onset of diabetes and in age-matched control rats. LA, in doses of 20, 50, and 100 mg/kg, was administered intraperitoneally five times per week after onset of diabetes.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>NBF in SDN was reduced by 50% LA did not affect the NBF of normal nerves but improved that of SDN in a dose-dependent manner. After 1 month of treatment, LA-supplemented rats (100 mg/kg) exhibited normal NBF. The most sensitive and reliable indicator of oxidative stress was reduction in reduced glutathione, which was significantly reduced in streptozotocin-induced diabetic and alpha-tocopherol-deficient nerves; it was improved in a dose-dependent manner in LA-supplemented rats. The conduction velocity of the digital nerve was reduced in SDN and was significantly improved by LA.</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>These studies suggest that LA improves SDN, in significant part by reducing the effects of oxidative stress. The drug may have potential in the treatment of human diabetic neuropathy.</jats:p> </jats:sec>

収録刊行物

  • Diabetes Care

    Diabetes Care 18 (8), 1160-1167, 1995-08-01

    American Diabetes Association

被引用文献 (5)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ